Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency
Efficacy and Safety of CinnaGen Recombinant Human Growth Hormone (CinnaTropin®) in Comparison With Novo Nordisk Growth Hormone (Nordilet®) Product in Pre-Pubertal Children With Idiopathic Growth Hormone Deficiency (IGHD)
Sponsor: Cinnagen
Listed as NCT03223025, this PHASE3 trial focuses on Idiopathic Growth Hormone Deficiency and remains completed. Sponsored by Cinnagen, it has been updated 6 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2023 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cinnagen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.